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Objective: Community pharmacy staff are responsible for obtaining and supplying unli-
censed “special” medicines to patients in primary care. Less well-defined parameters for safe 
and effective use of unlicensed compared to licensed medicines, along with issues around 
maintaining consistency between care settings or among manufacturers, have been associated 
with increased risks. This study aimed to explore the views and experiences of community 
pharmacy staff on accessing and supplying unlicensed “special” medicines to patients in 
Wales and the perceived impact of challenges faced on patient care.
Methods: A qualitative, phenomenological approach was employed, involving semi- 
structured interviews with pharmacists and pharmacy technicians working at one small 
chain of community pharmacies in Wales. The interview schedule focused on the personal 
experiences and perceptions of the participants on the processes involved in accessing and 
supplying unlicensed “special” medicines from a community pharmacy. Interviews were 
audio-recorded and transcribed verbatim.
Results: A total of six participants completed the interview. Three main themes were 
constructed from inductive thematic analysis of the transcribed interviews: requirement for 
additional patient responsibilities; influences on the confidence felt by pharmacy staff when 
accessing and supplying unlicensed “special” medicines; and continuity of supply.
Conclusion: This study gives a preliminary insight into the views and experiences of 
community pharmacy staff in Wales when accessing and supplying unlicensed “special” 
medicines. Further research is required to see if these views and experiences are representa-
tive of community pharmacy staff across the country.
Keywords: unlicensed medicines, “special” medicines, specials, community pharmacy, 
transfer of care, medicines supply, transmural care, off-label, compounding
Introduction
In the United Kingdom (UK), it is expected that medicines being sold and supplied 
to the public have undergone clinical trials and hold a license, or marketing 
authorisation1 granted by the Medicines and Healthcare products Regulatory 
Agency (MHRA). This license ensures a medicine has passed through clinical trials 
and has met the MHRA’s standards of safety and efficacy.2 However, sometimes 
there is no licensed product available to treat a patient’s specific clinical needs, for 
example, those in paediatric and elderly populations, as medicines are rarely tested 
and licensed for use within these age groups;3 those with rare diseases;4,5 those 
physically unable to take a licensed medicine, such as patients with dysphagia,6 or 
in times of drug shortages.7 When no suitable licensed product is available, 
unlicensed medicines, often known as ‘specials’ are supplied. Unlicensed “special” 
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medicines do not hold a marketing authorisation and there-
fore have not been held to the same standards of safety and 
efficacy testing as licensed medicines.8 It has been sug-
gested that the resulting less well-defined parameters for 
their safe and effective use, along with issues around 
maintaining consistency between care settings or among 
manufacturers,9 may lead to increased risks associated 
with their uses.10 Traditionally community pharmacists 
would compound special medicines within the 
pharmacy,11 however overtime, this role has changed. 
Internationally, community pharmacists have a more 
patient-focused role themselves12 and in the UK they 
obtain specials from a specials manufacturer who holds 
the required license.13
Many guidelines have been created to assist healthcare 
professionals in safely prescribing, accessing and supply-
ing unlicensed “special” medicines to patients. Donovan 
et al (2018)14 identified 52 of these guidelines that were in 
use within the UK during 2017 and analysed them using 
the Appraisal of Guidelines for REsearch and Evaluation 
instrument (AGREE) II tool. A lack of consistency was 
found in the guidelines with varying definitions for what 
an unlicensed “special” medicine is. Others have also 
found differing definitions between the General Medical 
Council (GMC) and the MHRA and it has been suggested 
that this variation may lead to confusion for healthcare 
professionals.15
A lack of consistency in the information supplied will 
inevitably lead to differing levels of understanding across 
care settings, and a range of perceptions on the accept-
ability of unlicensed “special” medicines among health-
care professionals, creating challenges for community 
pharmacists who are the point of contact for supply of 
specials in the community setting. The limited literature 
available from within the UK suggested that healthcare 
professionals have concerns over their legal responsibility 
when supplying unlicensed “special” medicines in primary 
care,16 and concerns over their use particularly in 
children,17 often associated with disruptions in prescribing 
of further supplies in primary care after patients have been 
discharged from hospital where the “special” was 
initiated.18 Studies have also highlighted difficulties for 
community pharmacy staff when sourcing medicines 
needed in the community setting.19 The difficulties experi-
enced were reported to lead to increased concerns for 
patients and carers and suggest a potential for suboptimal 
patient care for patients requiring unlicensed medicines in 
community, regardless of whether the unlicensed medicine 
was initiated in primary or secondary care. Despite this, 
there are a limited number of studies exploring the experi-
ences of community pharmacy staff with unlicensed med-
icines, within the UK.20 To the authors’ knowledge, there 
are no studies solely focussing on exploring healthcare 
professional views in Wales, where the responsibility for 
National Health Service (NHS) Wales lies within the 
Welsh Cabinet Secretary for Health and Social Service 
after devolution, even though almost £4m was spent on 
“specials” alone in Wales between August 2015 and 
July 2016 (Dr Mantzourani, email communication, 
January 3, 2019).
The aim of this study was to explore the views and 
experiences of community pharmacists and community 
pharmacy technicians who access and supply unlicensed 
“special” medicines in Wales and the perceived impact of 
challenges faced on patient care.
Methods
This study formed the first phase of a mixed methods 
approach, whereby quantitative methodology would be 
informed by a qualitative methodology. For the current 
study, a qualitative phenomenological approach with 
a constructivist outlook was adopted. This involved face 
to face semi-structured interviews.
Sample
A pragmatic approach was taken with a combination of 
convenience and purposive sampling. The sampling frame 
consisted of eight registered pharmacists and seven regis-
tered pharmacy technicians working at one small chain of 
community pharmacies in South Wales (number of phar-
macies = 7). Potential participants were required to have 
a minimum of 1-year experience working in a community 
pharmacy. All participants were presumed to be aged 18+ 
and able to give informed consent due to their profession 
and registration with the General Pharmaceutical Council, 
the regulatory body of pharmacy professionals in the UK.
Recruitment
One pharmacist, who worked within the chain of pharma-
cies sampled, agreed to act as a gatekeeper prior to the 
start of the study and was involved in disseminating the 
recruitment materials. Potential participants were identi-
fied and contacted by the gatekeeper through email 
between September and November 2018, and were sup-
plied with the study documentation, consisting of an email 
invitation, a participant information sheet, and a consent 
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form. All participants were informed of their right to with-
draw at any point and were instructed to either contact the 
gatekeeper to pass along their contact details to the 
researcher, or to contact the researcher directly. 
A reminder was sent out by email 2 weeks after the 
original email invitation had been sent, and again after 2 
months. The researcher had no access to identifying infor-
mation prior to a potential participant getting in touch with 
them to ask for information for the study.
Data Collection
Semi-structured interviews were chosen as the topic is an 
under-researched area and the method would allow indivi-
dual participants to raise issues of importance to them, that 
may not have been previously identified in the available 
literature. Data collection was conducted between 
September 2018 and January 2019, interviews were audio- 
recorded with consent, and transcribed verbatim, with each 
audio recording deleted immediately after transcription. 
The interview schedule focused on the processes involved 
when accessing and supplying unlicensed “special” medi-
cines, and the participants’ personal experiences related to 
this.
Data Analysis
Participants were anonymised during transcriptions and all 
identifiable information was removed. Inductive thematic 
analysis was chosen to analyse the interview transcripts, 
following the method suggested by Braun and Clarke.21 
NVivo® software was used to allow the researcher to code 
the transcripts, retrieve the codes and sort into subthemes 
and themes. A second researcher reviewed coding and 
independently assigned themes; any differences in coding 
were discussed and resolved.
Ethical Considerations
The study was reviewed and gained ethical approval from 
Cardiff School of Pharmacy and Pharmaceutical Sciences 
Research Ethics Committee in August 2018 (reference 
number 1718–28). All participants signed a consent form 
consenting to the recording of interviews and publication 
of their responses.
Researcher Characteristics and 
Techniques to Enhance Trustworthiness
The researcher collecting data is not a pharmacist, did not 
personally know any of the participants prior to 
conducting the interviews and had not experienced receiv-
ing an unlicensed “special” medicine, and as such had no 
predetermined views of what the participants’ experiences 
should be. The researcher aimed to meet the criteria for 
trustworthiness as described by Lincoln & Guba (1985),22 
and in an effort to increase rigour, transparency and replic-
ability, the structure of the report was based on the 
Standards for Reporting Qualitative Research 
(Supplementary Table 1).23
Results
Seven of the 15 potential participants who were invited to 
participate in the study initially agreed to take part, of 
which 6 proceeded to complete an interview within the 
data collection period (response rate 40%). All interviews 
were conducted face-to-face, taking place in the consulta-
tion rooms of the community pharmacies, and lasting 
between 15 and 40 minutes. Table 1 presents an overview 
of the participants’ interview number, work experience 
and the average number of unlicensed “special” medicines 
dispensed per month at their workplace. Certain demo-
graphic information such as occupation, age, sex and the 
previous work experience of participants are not presented 
to prevent the possibility of identifying participants from 
the small sampling frame available. Inductive thematic 
analysis of transcribed interviews revealed three main 
themes: requirement for additional patient responsibilities; 
influences on the confidence felt by pharmacy staff when 
accessing and supplying unlicensed “special” medicines; 
and continuity of supply (Figure 1). Further examples of 
Table 1 Overview of Relevant Participant Demographics and 
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representative quotes for each theme can be seen in 
Supplementary Table 2.
Theme 1: Requirement for Additional 
Patient Responsibilities
Participants described how patients receiving unlicensed 
“special” medicines held additional responsibilities com-
pared to receiving licensed medication. Patient awareness 
and understanding of the challenges associated with acces-
sing and supplying of specials was perceived as vital in 
ensuring the patient successfully took on these additional 
responsibilities, and strategies used as communication 
tools to improve patient outcomes were highlighted.
Importance of Patient Awareness and Understanding 
of the Implications of Receiving Unlicensed “Special” 
Medicines
Patient awareness of the implications of receiving unli-
censed “special” medicines was identified as essential in 
ensuring the increased responsibilities were taken on board 
consistently by the patients.
[Patients need] an understanding that [unlicensed ‘special’ 
medicines are] not something that we can just take off the 
shelf, that, we need a little bit of warning, that we can’t 
order it in advance without having the prescription . . . and 
they need to allow us enough lead time. [INT2] 
Clearly explaining issues that patients would need to be 
aware of was perceived as part of the pharmacy staff role. 
However, it was noted that a balance was needed between 
informing the patient about differences between their unli-
censed and licensed medicines and reassuring them in 
relation to potential risks.
I try not to bombard [patients] too much with, a lot of 
information about what has and hasn’t happened in the 
past, in terms of testing [for unlicensed ‘special’ medi-
cines] because, you’ve got to get the balance between 
informing [patients] of what’s going on, but also, not 
saying too much to kind of worry them and put them off 
taking it. [INT4] 
This balance was required as patients tend to have 
increased concerns once they have been fully informed 
about the potentially limited evidence available for unli-
censed “special” medicines, occasionally leading to the 
questioning of the need for the medicine itself.
One of the common discussions I will have [with parents is] 
well you know, ‘is this really necessary?’ and the other thing 
is ‘is my child being used as an experiment?’. [INT1] 
Patient Initiated Ordering of Further Supplies
Participants reported relying on patients to inform them in 
advance of when further supplies would be needed and 
Figure 1 Themes and subthemes identified by thematic analysis of semi-structured interviews with community pharmacy staff (pharmacists and registered technicians).
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discussed the main reasons why patients were required to 
continuously initiate ordering within the community.
I think because of the cost of the special we wouldn’t have 
kept it in [the pharmacy] just in case, especially with it only 
having a 28-day expiry . . .. so If we ordered it in advance 
and then [the patient] didn’t come in for another week or so, 
then it’s cutting into the expiry of the actual item. [INT3] 
The need for patient-led management of the ordering was 
deemed critical in order to allow enough time for phar-
macy staff to obtain the supply and was clearly explained 
to patients when they initially presented a prescription for 
an unlicensed medicine to the community pharmacy or 
when a formulation or dose would change.
Because you know, [unlicensed ‘special’ medicines are] 
not the run of the mill drugs, you just sit [the patient] 
down and have a little run through, and also they know 
that the, the process is different, once, once they’ve had 
the drug a couple of times they get to know and they will 
often ring me. [INT1] 
Theme 2: Influences on the Confidence 
Felt by Pharmacy Staff When Accessing 
and Supplying Unlicensed “Special” 
Medicines
Participants outlined multiple factors that affected their con-
fidence when accessing and supplying unlicensed “special” 
medicines. The complexity of the medicine itself and the 
amount of information received with the prescription or med-
icine led to a decrease in confidence. However, concerns were 
reduced through the professional trust felt across settings and 
the participant’s own personal experience within the role.
Ambiguity About Classification and Processing of 
Unlicensed “Special” Medicines
Varying definitions of the term unlicensed medicines were 
reported, with some participants describing the lack of 
license for a particular use and others encompassing the 
concept of off-label medicines.
[An unlicensed ‘special’ medicine is] something that’s 
being used away from the product license, meds [sic] 
that are licensed for one use and then used for different 
conditions. [INT3] 
The wide range and variety of unlicensed “special” med-
icines available were perceived to add to the complexity 
and the increased anxiety when processing prescriptions, 
especially when receiving prescriptions for items that were 
unusual or unfamiliar to pharmacy staff.
If we’ve only got one patient on [an unlicensed ‘special’ 
medicine] and I can’t find anything where another patient 
has been on a dose similar or, or used in that indication 
then perhaps I might be a little bit more cautious. [INT4] 
In these cases, participants highlighted the need to spend 
time researching the literature on the clinical efficiency of 
the products, in order to feel confident enough to continue 
with a prescription.
Information Needs for Safe Transfer of Care Across 
Settings
A lack of clinical information accompanying new pre-
scriptions for unlicensed “special” medicines was reported 
and participants explained how they would often need to 
seek further information across settings before feeling 
confident enough to complete the clinical checks required. 
All participants agreed that for new prescriptions they 
needed to seek further information from the prescriber.
One participant described how providing background clin-
ical information on prescriptions could help to reduce the 
workload within the pharmacy and increase the confidence 
felt.
It took a call to the surgery, a call to the hospital and a call 
to the patient, whereas if I’d had that information with the 
prescription, ‘this is an unlicensed medicine, the dose has 
been checked by a kidney specialist, the patient has been 
on it for years and years’, well, and it goes on, thatwould 
probably have saved me a bit of time. [INT4] 
Professional Trust
Despite the lack of confidence reported above, participants 
described how the professional trust felt towards manufac-
turers involved in the supply chain helped to reassure 
them, and reduce concerns around the use of unlicensed 
“special” medicines. Trust was also reported towards the 
clinician who initiated the prescription for an unlicensed 
“special” medicine, who was perceived to hold specialist 
knowledge and experience.
If the prescriber [GP] tells me that the consultant or the 
specialist in a unit somewhere has prescribed [the unli-
censed ‘special’ medicine], then that person has expertise 
in prescribing that kind of drug, in which case, although 
I might not feel comfortable with it, I wouldn’t go against 
what somebody says if they’ve got twenty years’ experi-
ence in a field. [INT4] 
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One participant gave an example of how that professional 
trust of a prescriber in primary care reinforced their own 
preconceptions about the need to continue the supply of 
a specific unlicensed medicine.
We’ve had it with the Armour Thyroid, where some sur-
geries have started to refuse doing that, you know . . . but 
they’re basing it on NICE guidance and, health authority 
guidance, so you know I’m not going to argue with that 
because, to be honest, I, don’t, think, we should be paying 
hundreds of pounds for it either . . .. [INT2] 
Association of Confidence with Experience Within 
the Role
Participants who had more experience within their role 
reported feeling more confident about their responsibilities 
when supplying unlicensed “special” medicines and con-
sidered it as an integral part of their work activities.
One participant reflected on their own experiences and 
described how their concerns in relation to unlicensed 
medicines when first taking on the role of a community 
pharmacist had decreased, and their confidence had 
increased over time.
I think when I first qualified, even a one daily [unlicensed 
‘special’ medicine] kept me up in the night cause it’s the 
first time I ever really signed things like that away, but 
I think in the start when doses were different to what 
you’d see with licensed items it was a bit, hard to sign 
it, just purely because no experience, and the worry that 
something might possibly happen to the patient and that 
my name is against it . . ..but as time has gone on, with 
experience, I know the right calls to make. [INT4] 
Theme 3: Continuity of Supply
Participants described how factors such as keeping addi-
tional records about the unlicensed medicines supplied and 
the use of an online ordering system contributed positively 
to maintaining continuity of supply. However, tensions 
between care settings and issues with the accessibility 
and availability of the medicines were still experienced, 
occasionally resulting in supply delays or even treatment 
disruption.
Additional Record Keeping
Additional record keeping was described as a requirement 
before authorising the ordering of an unlicensed medicine, 
both in the patient medication record but also on a separate 
file. The recording of all the additional information was 
perceived as helpful for future re-ordering because it 
increased transparency.
If it’s something new, then I’m likely to, do it myself first, 
find out where we get [the unlicensed medicine] from, 
then we put a note on the patients record so that in future, 
somebody else could continue the ordering. [INT4] 
Participants explained how the additional records kept 
were also useful when dealing with external queries from 
pricing bureaus about the cost of the medicines for reim-
bursement, especially in the case of very expensive items.
Notes were also kept of discussions with patients, so 
the participants had a record of the patients acknowledging 
the supply of, and details around, unlicensed medicines.
I confirm with the prescriber and understand the patient 
knows exactly, what the dose is, the fact that the dose is 
not licensed, and I usually document that on their records 
then to say they’ve acknowledged it. [INT4] 
Tensions Within and Between Care Settings
Participants described how inaccuracies in selecting the 
correct product on the GP prescribing software when 
licensed alternative medicines were suitable, could lead 
to friction between pharmacy and GP staff, with increased 
workload while the prescription was corrected and poten-
tial for increased costs to the NHS.
I mean we had some last year, with the flu vaccination and 
two of the [GP] surgeries I think, or it might even have 
been three of the surgeries, picked the specials liquid for 
the anti-viral by mistake, instead of the licensed one, 
which was going to cost an absolute arm and a leg. [INT2] 
The inaccurate selection of unlicensed medicines when 
licensed alternative medicines were suitable, was reported 
to lead to an increased workload within the pharmacy and 
delayed supply, while the prescription was corrected.
Examples of differences in the perceived benefit of 
unlicensed medicines between staff in the same GP sur-
gery were also given, particularly when the responsibility 
of prescribing moved to a different GP.
We’ve had a few [instances] where historically the GP has 
prescribed [an unlicensed medicine] and then where the 
GP that had prescribed it has retired, and then the new GP 
is going ‘why are we doing this?, I’m not doing this’. 
[INT2] 
Tensions were also mentioned in the interface of primary 
and secondary care, mainly linked to different acceptability 
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and perceptions of the potential benefit of unlicensed med-
icine by healthcare professionals across care settings.
In hospitals they’ve got consultants, and consultants have 
a far wider brief, as regards to prescribing, so they can step 
outside of certain limitations and when a patient then is 
transferred to the community, what was ok in a hospital is 
not necessarily ok with the community GP. [INT1] 
Participants explained how the tensions described above 
can directly impact the continuity of supply, with indivi-
dual perceptions of acceptability causing disruption in 
timely access to the medicines.
I have one parent who, the surgery will often have a locum 
in place, and I understand if the locum doesn’t feel com-
fortable about signing a repeat prescription for this [unli-
censed] drug, but it’s landing that patient’s care . . . you 
know suddenly their, perhaps their regular doctor might 
not be in until the Friday. [INT1] 
Challenges with Accessibility and Availability
In addition to different attitudes towards unlicensed med-
icines, multiple issues were reported with the accessibility 
and availability of unlicensed “special” medicines. Lack of 
availability of specific formulations of the unlicensed med-
icines resulted in disruption of supply and increased work-
load for the pharmacy staff, who had to change suppliers 
in order to access the medicine.
The inconsistent availability and varying timelines 
involved in accessing unlicensed medicines also posed 
a challenge. An example of manufacturing issues was pro-
vided, which led to a sudden increase in the timeline involved 
when obtaining a specific unlicensed medicine. Pharmacy 
staff had to adapt the ordering process to ensure continuity of 
supply. One participant described how the lack of accessi-
bility of a specific medicine from the manufacturer, coincid-
ing with a lack of availability between pharmacies and across 
care settings, led to treatment disruption for a patient.
Three years ago . . . we were unable to get the medication in 
and the patient had a lapse of three days . . ..in this case, no 
other pharmacy could supply . . ..the hospital couldn’t supply 
after . . ..and so the patient was without medication for three 
days, they were monitored and they didn’t suffer adversely, 
but it’s not a situation that I would ever like to be in. [INT1] 
Perceived Advantages of Online Ordering
Most of the participants involved in the study were using 
the same main supplier for unlicensed medicines, which 
offered an online ordering system. This option for digital 
ordering facilitated workload and led to minimal delays, 
not only as the process did not involve time-consuming 
phone calls but because it also adopted a “named patient” 
concept. With this approach, an initial order was linking 
a specific product with an individual patient, and any 
subsequent orders were using the same information by 
default.
The thing about a special, the patient needs it, fairly quickly 
and what we’ve found with this particular company is they 
understand that, we can order online, they respond to the 
order, the details, all the details go on, including the name of 
the patient ok, we do it as a named patient, it improves 
tracking . . ..rather than just give them a number, we do it 
under a named patient issue [INT1] 
One pharmacy had not yet switched over to an online 
supplier and highlighted the longer process involved 
when ordering unlicensed “special” medicines.
We’ve got sort of fact sheets that we use for our regular 
specials, so it’s like a pro forma that we use, we’ll fax that 
off to the manufacturer, they’ll give us a ring back to 
confirm it, they’ll then send us an email, with everything 
in confirming it, letting us know what they expiry date is, 
pack sizes and if there’s any issues, we’ll then reply to that 
email confirming it and then it’ll come in, they’ll usually 
tell us when we’ll be getting it as well [INT2] 
The participant was aware of an upcoming change of 
suppliers and anticipated the use of technology would 
help streamline the process of ordering and benefits of 
online tracking.
Discussion
The aim of this study was to explore the views and 
experiences of community pharmacy staff who access 
and supply unlicensed “special” medicines in Wales. To 
the authors’ knowledge, this is the first study in Wales that 
describes the challenges experienced by pharmacy staff 
and the resulting adaptations to the workflow that are put 
in place to optimise patient care. Despite these efforts, the 
lack of a coherent, consistent, integrated, and transparent 
pathway between care settings meant issues were still 
experienced that led to delays and disruption in the con-
tinuity of supply.
Participants described varying levels of confidence in 
their role of accessing and supplying unlicensed “special” 
medicines. The differing definitions they provided 
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themselves for an unlicensed “special” medicine reflect the 
wider variation and inconsistencies in the information seen 
in guidance available to healthcare professionals within 
the UK. It has been suggested that this lack of consistent 
information is another contributing factor to the propaga-
tion of the risks associated with the use of unlicensed 
“special” medicines24 and this study further supports the 
highlighted need for clearer information to be created for 
healthcare professionals across care settings.25
Transfer of care between settings has been noted by the 
World Health Organisation as a major area where medica-
tion errors occur.26 In response, various initiatives have 
been developed internationally to improve communication 
around discharge and minimise the associated risks, as 
community pharmacists do not traditionally receive infor-
mation across settings about discharge medicines.27 One 
of the main challenges reported by participants in this 
study, was the lack of accompanying clinical information 
provided with prescriptions initiating therapy with an unli-
censed medicine in primary care or continuing with 
a therapy introduced in secondary care, explaining how 
they often needed to seek further information from a range 
of resources about the medicine before feeling confident 
enough to proceed with the supply. This was usually 
accompanied by keeping additional records compared to 
licensed medicines not only as a legal requirement1 but 
also as a means of increasing transparency within the 
workplace and across care settings, as well as for docu-
menting their professional judgement as discussed in gui-
dance by the professional (Royal Pharmaceutical Society) 
and regulatory (General Pharmaceutical Council) bodies 
for pharmacists in the UK.28,29
In Wales transfer of care between hospital and com-
munity is facilitated by the national community pharmacy 
Discharge Medicines Review Service introduced in 2013 
and rolled out nationally in 2015.30 The DMR service has 
been shown to be associated with decreased hospital 
readmissions,31 its value further reinforced by Welsh 
Government in its response to a global pandemic by 
being the only advanced service maintained in community 
pharmacies.32 Despite this, and even though the need for 
clinical information to be made accessible for community 
pharmacists has been recognised in the literature and seen 
as a method of improving continuity after discharge,33 the 
DMR and other such schemes do not usually provide 
clinical reasons for medication changes during a patient’s 
in-hospital stay. Additionally, many unlicensed medicines 
are initiated in secondary care by specialist consultants in 
outpatient clinics, with no established pathway to commu-
nicate clinical reasoning to the follow-up prescriber and 
community pharmacist in primary care. Participants 
reported feeling reassured from the perceived specialist 
knowledge and experience of the hospital prescriber, and 
this trust reduced their concerns and increased their con-
fidence to proceed with the supply, similarly to outcomes 
reported elsewhere in the literature.34 Professional trust is 
vital when working as part of a team with improved 
patient outcomes as a goal. However, and despite evidence 
to suggest community pharmacy staff can play a crucial 
role in assisting patients during care transfers,35 and that 
allowing community pharmacists insight of and input into 
full patient records would enable them to make informed 
decisions and increase patient safety (Pharmaceutical jour-
nal 2019),36 the exchange of clinical information between 
GPs and community pharmacists is reported in the litera-
ture as suboptimal.37
Integrated care pathways, outlining the patient journey 
and detailing what should happen at each step during 
treatment, have been in use in the UK for a range of 
different conditions.38 Used as a means to improve con-
sistency and patient experience, care pathways have been 
found to be beneficial in improving clinical outcomes,39 
interprofessional teamwork40 and in providing a basis for 
recommendations to improve services.41 A lack of an 
established care pathway for unlicensed medicines was 
shown in this study to impact on the perceived responsi-
bility of key stakeholders, with prescribing clinicians in 
secondary care transferring the responsibility for further 
prescribing and supplies to the general practitioner and 
community pharmacist to share.42
Participants discussed how different awareness levels 
around, and perceptions of this responsibility, often led to 
delays or disruptions of the continuity of supply, for 
example, with GPs unintentionally prescribing unlicensed 
medicines or refusing to prescribe the unlicensed medicine 
required. This has been reported previously in the UK with 
GPs giving costs, lack of available evidence, or personal 
inexperience, as reasons to refuse to continue prescriptions 
for unlicensed medicines.18 Organisations such as the 
international foundation for integrated care have been 
developed that provide an education network with 
a focus on integrated care and aims to improve patient 
care by sharing the perspectives of those throughout the 
different healthcare settings.43 The issues around trans-
mural care (ie where primary and secondary care interact) 
identified in this study and described above provide further 
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evidence to support that an establish care pathway, inte-
grating a short, standardised template with key clinical 
information to accompany each prescription from one set-
ting to another, as suggested by one participant, would 
help to reduce the workload within the pharmacy and the 
GP surgeries when dealing with unlicensed medication, 
increase the confidence felt by primary care staff and 
ultimately improve patient safety. The previous and 
repeated individual experience was found to be associated 
with increased levels of confidence when supplying an 
unlicensed medicine in this study, in line with literature 
reporting how community pharmacists build their under-
standing of unlicensed and off-label medicines through 
their experiences within their role.44 This experience is 
usually built post registration, as Undergraduate pharmacy 
curricula do not traditionally include guidance on how to 
use unlicensed medicines as an explicit clinical topic due 
to its complexity.45 In the USA, the national Association 
of Speciality Pharmacy offers continued education for 
healthcare professionals around speciality pharmacies and 
speciality medications.46 No similar body exists in the UK. 
However, structured and targeted support for continuous 
professional development on unlicensed medicines pro-
vided by existing national institutions such as Health 
Education England (HEE) and Health Education and 
Improvement Wales (HEIW) can ensure consistency of 
information and lead to increased levels of confidence 
for all pharmacy staff.
Another key concept that was discussed by participants 
was the additional responsibility that patients receiving 
unlicensed medicines were required to take compared to 
patients on traditional medicines, an issue of concern con-
sidering that it has been suggested the general public in the 
UK have little awareness of the use of unlicensed “spe-
cial” medicines.47 Varying timelines required to access the 
medicines, inconsistent bioequivalence in the products 
available and short expiry dates preventing automatic 
stock re-ordering were some of the issues highlighted by 
the participants and reported previously in the 
literature.19,48,49 This led to an increased need to negotiate 
shared goals with the patient as part of a patient-centred 
approach, with patients needing to maintain and manage 
communication across settings and often to take responsi-
bility for initiating the ordering of further supplies, critical 
to ensure the best possible outcomes.50,51 The resulting 
increased involvement of patients in their care had to be 
achieved by maintaining the balance of providing addi-
tional information about unlicensed “special” medicines 
without causing concern. Participants gave examples of 
concerns raised by patients consistent with that in the 
literature, showing increased concern once fully informed 
about the use of unlicensed medicines,19,52,53 one partici-
pant explained how parents often questioned the need for 
the unlicensed medicine prescribed for their child, suggest-
ing that the concerns and perceptions highlighted may lead 
to non-adherent behaviours.54,55 Literature reports the suc-
cessful use of a range of educational interventions to 
increase patient awareness on medication use for different 
conditions.56,57 Development of such educational interven-
tions, with patient input to ensure they meet the needs of 
the end-user,58 can be one way of informing patients about 
the uses and implications of receiving an unlicensed “spe-
cial” medicine without causing concerns. Patients may 
benefit from the development of a common resource for 
information, for example, a booklet explaining what unli-
censed “special” medicines are and providing some back-
ground using patient-tailored language. These have been 
produced locally within the UK59 but have not been stan-
dardised for more widely adopted use.
One aspect participants in this study identified in improv-
ing the continuity of supply was the use of the online ordering 
system. Participants described how this technology helped to 
reduce the workload when ordering unlicensed “special” 
medicines and allowed for better communication between 
care settings, supporting even further the examples in the 
literature of how technology can be successfully integrated 
into community pharmacy practice,60 with resulting benefits 
on patient care.61,62 Despite this, some participants were still 
using outdated forms of technology such as fax machines to 
place orders to suppliers, even though they have been linked 
to increasing security risks and expenses within community 
pharmacy.63 The results of this study suggest that community 
pharmacies may benefit from using an online ordering sys-
tem and upgrading technological equipment where practical.
The department of health and social care (2019)64 has 
highlighted the issues associated with cost when accessing 
unlicensed “special” medicines. One option for their sup-
ply is directly from the hospital setting in which they are 
initiated, or from an NHS approved supplier. Some coun-
tries have responded to challenges associated with the 
increasing cost of external manufacturing of specials by 
introducing small-scale manufacturing by pharmacy 
departments in hospitals, on a patient named basis.65–67 
A study conducted within the UK explored the impact of 
having unlicensed “special” medicines supplied directly by 
the hospital to children in the community, and showed 
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a significant reduction in cost.68 When unlicensed “spe-
cial” medicines cannot continue to be supplied directly by 
the hospital, commercial suppliers can charge higher fees/ 
prices to cover the one-off formulations and production in 
their facilities, as they are not made on a commercial 
scale,69 and any post-production quality assurance testing. 
If the medicine is listed in the relevant Part VIIIB section 
of the Drug Tariff, then a pre-set price will be reimbursed 
to community pharmacy by the NHS.70 However, many 
unlicensed “special” medicines are not listed in the drug 
tariff, allowing suppliers to set their own prices for these 
medicines, leading to huge variations. Lack of prescribers’ 
awareness of these substantial costs and of cheaper alter-
natives was reported in this study, suggesting an unneces-
sary burden on healthcare costs that can be targeted for 
a more efficient system. The department of health and 
social care (2019) suggested a central service that would 
supply all specials that are not included in Part VIIIB of 
the Drug Tariff, and further work is underway to explore 
requirements for this mechanism.64
Limitations
The sample used in the study only involved a small num-
ber of participants working in one small chain of pharma-
cies in South Wales and therefore results may not be 
generalisable across all community pharmacies. However, 
the results offer an insight into the views and experiences 
some community pharmacy staff face when accessing and 
supplying unlicensed “special” medicines in Wales and 
form the base for developing a survey to be used in future 
research.
Future Work
Some topics were not raised by the participants in this 
study, such as the process and experiences related to 
importing unlicensed “special” medicines into the UK, 
and the similarities and differences between the views 
and perceptions of staff in different pharmacy settings 
such as independent, smaller and larger national chains.
The results of this study will be used alongside existing 
literature and stakeholder input to create a survey that will 
be disseminated to a wider sample of community phar-
macy staff across Wales. This project is also part of 
a larger study not only exploring the views and experi-
ences of community pharmacy staff but also primary and 
secondary care clinicians who prescribe, and patients who 
receive, unlicensed “special” medicines.
Conclusion
This study identified several factors that impact on pharmacy 
staff supporting patients receiving unlicensed medicines 
throughout their journey, from initial prescribing to continu-
ing supply. Results suggest that an integrated, transparent 
care pathway that follows the patient across all care settings 
will result in reduced clinical risk and logistical problems 
associated with the transfer of care. Tailored support mechan-
isms for patients and healthcare professionals may provide 
further reassurance to the former and increase the confidence 
of the later, so a patient-centred approach can be adopted at 
all times. Further research on exploring the option of 
a hospital or centralised NHS-led supply may also be crucial 
to shaping a national strategy for reducing unnecessary costs 
often associated with supplies of unlicensed medicines.
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